CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
aspirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000500
NCT00000500Phase 3Completed
CompareCT.gov

Physicians' Health Study

Brigham and Women's Hospital·interventional·Posted Oct 28, 1999·Updated Jan 28, 2021

In Brief

A Phase 3 clinical trial evaluating aspirin and carotene for Cardiovascular Diseases and 3 related conditions. Completed.

Detailed Summary

To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia
Countries--
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
19811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1981
Primary CompletionDec 1, 1995
Study CompletionDec 1, 1996
TodayJul 2, 2026
Enrollment to primary: 14.3 yearsPosted 26.7 years ago

Interventions

aspirindrug

carotenedrug